Joseph P. Hagan Sells 115,290 Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) Stock

Regulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report) CEO Joseph P. Hagan sold 115,290 shares of Regulus Therapeutics stock in a transaction on Monday, January 13th. The shares were sold at an average price of $1.26, for a total value of $145,265.40. Following the completion of the transaction, the chief executive officer now owns 222,572 shares of the company's stock, valued at approximately $280,440.72. The trade was a 34.12 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Regulus Therapeutics Trading Up 3.7 %

Shares of RGLS traded up $0.05 during trading hours on Wednesday, hitting $1.27. 283,082 shares of the stock traded hands, compared to its average volume of 348,120. The business has a fifty day moving average of $1.53 and a 200-day moving average of $1.59. The firm has a market capitalization of $83.19 million, a PE ratio of -1.19 and a beta of 1.60. Regulus Therapeutics Inc. has a 1-year low of $1.08 and a 1-year high of $3.79.

Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.03). As a group, equities research analysts expect that Regulus Therapeutics Inc. will post -0.88 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Regulus Therapeutics

Several large investors have recently bought and sold shares of the business. Creative Planning acquired a new stake in Regulus Therapeutics during the 3rd quarter worth $26,000. SG Americas Securities LLC bought a new position in shares of Regulus Therapeutics in the 3rd quarter worth $33,000. Jane Street Group LLC bought a new position in shares of Regulus Therapeutics in the 3rd quarter worth $46,000. State Street Corp grew its stake in shares of Regulus Therapeutics by 3.5% during the third quarter. State Street Corp now owns 1,000,998 shares of the biopharmaceutical company's stock worth $1,572,000 after purchasing an additional 33,496 shares during the period. Finally, Victory Capital Management Inc. increased its holdings in Regulus Therapeutics by 10.4% in the third quarter. Victory Capital Management Inc. now owns 398,866 shares of the biopharmaceutical company's stock valued at $626,000 after purchasing an additional 37,480 shares during the last quarter. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

RGLS has been the subject of a number of research reports. HC Wainwright restated a "buy" rating and issued a $10.00 target price on shares of Regulus Therapeutics in a research note on Monday, November 11th. StockNews.com raised shares of Regulus Therapeutics to a "sell" rating in a report on Tuesday, September 17th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $10.80.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.